Aspirin Resistance

Hellenic Journal of Cardiology

Volumn 45, Issue 1, 2004, Pages 1-5

  Deliargyris, Efthymios N ^a,b   Boudoulas, Harisios ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b NONE   (Greece)

Author keywords

Aspirin; Pharmacogenetics; Platelets

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; EPTIFIBATIDE; ESTROGEN; FIBRINOGEN RECEPTOR; IBUPROFEN; INDOMETACIN; PLACEBO; THROMBOXANE A2;

BLEEDING TIME; CHROMOSOME 17; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; EDITORIAL; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MORTALITY; PERIPHERAL VASCULAR DISEASE; PHARMACOGENETICS; SMOKING; STROKE; THROMBOCYTE AGGREGATION; UNSTABLE ANGINA PECTORIS; URINE LEVEL; VOLUNTEER;

EID: 0842305877     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (39)

1. Jack DB: One hundred years of aspirin. Lancet 1997; 350: 437-439.
2. de Gaetano G: Historical overview of the role of platelets in hemostasis and thrombosis. Haematologica 2000; 85: 3-10.
3. Roth GJ, Majerus PW: The mechanism of the effect of aspirin on human platelets. J Clin Invest 1975; 56: 624-632.
4. 2 synthase-1. Nature 1994; 367: 243-249.
5. 2 synthase. Nat Struct Biol 1995; 2: 637-643.
6. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. Br Med J 2002; 324: 71-86.
7. Second International Study of Infarct Survival Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360.
8. Steering Committee of the Physicians' Health Study Research Group. Preliminary report: findings from the aspirin component of the ongoing physician's health study. N Engl J Med 1988; 318: 262-264.
9. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989; 321: 129-135.
10. Metha J, Metha P, Burger C, Pepine CJ: Platelet aggregation studies in coronary artery disease. Atherosclerosis 1978; 31: 169-175.
11. Buchanan MR, Brister SJ: Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically. Can J Cardiol 1995; 11: 221-227.
12. Hurlen M, Seljeflot I, Arnesen H: The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction. Scand Cardiovasc J 1988; 32: 233-237.
13. Pappas JM, Westengard JC, Bull BS: Population variability in the effect of aspirin on platelet function. Arch Pathol Lab Med 1994; 118: 801-804.
14. Grotemeyer KH: Effects of acetylsalicylic acid in stroke patients; evidence of nonresponders in a subpopulation of treated patients. Thromb Res 1991; 63: 587-593.
15. Grotemeyer KH: Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403.
16. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, et al: Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-1007.
17. Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, et al: Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. Am J Cardiol 1999; 83: 1147-1151.
18. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
19. Hung J, Lam JYT, Lacoste L, Letchavobski G: Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432-2436.
20. Livio M, Del Maschio A, Cerletti C, de Gaetano G: Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclooxygenase activity. Prostaglandins 1982; 23: 787-796.
21. Rao GHR, Johnson GG, Reddy KR, White JG: Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 1983; 3: 383-388.
22. Zimmerman N, Kienzle P, Weber AA, Winter J, Gams E, Schrör K, Hohlfeld T: Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 121: 982-984.
23. Mitchell JA, Akaarasereenot P, Thiemermann C, Flower RJ, Vane JR: Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci 1993; 90: 11693-11697.
24. Weber AA, Zimmermann KC, Myerer-Kirchrath J, Schrör K: Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 33: 900.
25. Patrignani P, Sciulli MG, Manarini S, Santini G, Cerletti C, Evangelista V: COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 1999; 50: 661-677.
26. Newman PJ, Derbes RS, Astor RH. The human platelet alloantigens, P1A1 and P1A2, are associated with a leucine 33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989; 83: 1778-1781.
27. Stakos D, Boudoulas H: Pharmacogenetics and Pharmacogenomics in Cardiology. Hell J Cardiol 2002; 43: 1-15.
28. Sperr WR, Huber K, Roden M, Janisiw M, Lang T, Graf S, et al: Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young central Europeans. Thromb Res 1998; 90: 117-123.
29. 3 integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001; 104: 2666-72.
30. A polymorphisms display different sensitivities to agonists. Circulation 2000; 101: 1013-1018.
31. A2 polymorphism and efficacy of aspirin. Lancet 1998; 351: 1253.
32. Undas A, Sanak M, Musial J, Szczeklik: Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 1999; 353: 982.
33. A polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bb 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation 1997; 96: 1424-1431.
34. A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349: 385-388.
35. A2 homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men. J Am Coll Cardiol 2003; 42: 661-667.
36. A polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. Arch Pathol Lab Med 2001; 125: 112-115.
37. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
38. CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J of Med 2001; 345: 494-502.
39. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W: Monitoring of aspirin (ASA) pharmacodynamics with the platelet function Analyzer PFA-100®. Thromb Haemost 2000; 83: 316-321.